Please try another search
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
| Name | Age | Since | Title |
|---|---|---|---|
| Carlos Manuel Buesa Arjol | - | 2000 | Co-Founder, Chairman, CEO & President |
| Leon Hooftman | - | - | Member of Clinical Advisory Board - Oncology |
| Felipe Prosper Cardoso | - | - | Member of Clinical Advisory Board - Oncology |
| Jose Luis Molinuevo | - | - | Member of Scientific Advisory Board |
| Lori Anne Kunkel | 67 | 2018 | Member of Clinical Advisory Board - Oncology |
| Ana Limon Carrera | - | 2022 | Member of Clinical Advisory Board - Oncology |
| Manuel López-Figueroa | - | 2020 | Lead Independent Director |
| Douglas V. Faller | 72 | 2022 | Member of Clinical Advisory Board - Oncology |
| Luis Sanchez Quintana | - | 2025 | Independent Director |
| Konstantinos Alataris | 55 | 2025 | Independent Director |
| Pierre Beaurang | 53 | 2025 | Independent Director |
| Eric Hollander | - | 2025 | Member of Clinical Advisory Board - CNS |
| Montserrat Vendrell | - | 2025 | Independent Director |
| Sarah Fineberg | - | 2025 | Member of Clinical Advisory Board - CNS |
| Alan F. Schatzberg | 80 | 2025 | Member of Clinical Advisory Board - CNS |
| Emil F. Coccaro | - | 2025 | Member of Clinical Advisory Board - CNS |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review